Shannon E. Boye, Ph.D., an assistant professor in the University of Florida College of Medicine’s department of ophthalmology, discusses her research involving developing gene therapies for devastating forms of blindness.
Dr. Boye received the Foundation’s Board of Director’s Award, which was presented at VISIONS 2015, FFB’s annual conference, for achievements in retinal research.
In medicine, doctors often talk about treatments, but rarely about cures. Now, gene therapy is offering the potential to actually cure certain diseases and an experimental breakthrough could one day help blind patients see.
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness. Leber congenital amaurosis type 1 (LCA-1)…
Much work is being done with Adeno-associated virus (AAV) vectors for application in retinal gene therapy, with modifications being made to the capsid and genome of the vector to generate novel variants with unique transduction profiles, according to Shannon Boye, PhD…
Dr. Boye and her research team received a $900,000 grant for a gene therapy project targeting Leber congenital amaurosis.
It’s usually in the first few months that parents of newborns with Leber congenital amaurosis realize something is wrong. The babies fail to focus on their parents’ faces, may be abnormally sensitive to light or have unusual eye movements. Parents then receive the devastating diagnosis: severe, permanent visual impairment.